Vident Investment Advisory
SAGE icon

Vident Investment Advisory’s Sage Therapeutics SAGE Stock Holding History

Vident Investment Advisory’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,745
Closed -$213K – 1223
2021
Q2 		$213K Buy
+3,745
New +$265K 0.01% 1031
2020
Q1 		– Sell
-4,031
Closed -$291K – 845
2019
Q4 		$291K Sell
4,031
-106
-3% -$13K 0.02% 646
2019
Q3 		$580K Buy
4,137
+35
+0.9% +$5.86K 0.05% 290
2019
Q2 		$751K Buy
4,102
+297
+8% +$50.7K 0.06% 215
2019
Q1 		$605K Buy
3,805
+183
+5% +$26.5K 0.03% 511
2018
Q4 		$347K Sell
3,622
-230
-6% -$26.3K 0.02% 678
2018
Q3 		$544K Sell
3,852
-3,872
-50% -$598K 0.02% 658
2018
Q2 		$1.21M Buy
7,724
+961
+14% +$151K 0.05% 392
2018
Q1 		$1.1M Buy
+6,763
New +$1.15M 0.04% 377

Other funds holding SAGE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vident Investment Advisory's SAGE Position: Q3 2021 in Review

Vident Investment Advisory sold out of Sage Therapeutics (SAGE) in Q3 2021, closing a stake of 3,745 shares — an estimated $213K sold.

Vident Investment Advisory first reported a position in SAGE in Q1 2018 and held it in 9 quarters. The position peaked at $1.21M in Q2 2018. 226 funds tracked by Wall St. Rank hold SAGE as of Q3 2021.

  • Vident Investment Advisory reported no remaining Sage Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Vident Investment Advisory sold 3,745 Sage Therapeutics shares in Q3 2021, an estimated $213K.
  • Vident Investment Advisory first reported a position in Sage Therapeutics in Q1 2018 and held it in 9 quarters.
  • Vident Investment Advisory's Sage Therapeutics position peaked at $1.21M in Q2 2018.
  • 226 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2021.

Based on Vident Investment Advisory's 13F filing for Q3 2021, filed 12 Nov 2021.